Panipenem-betamipron and decreases in serum valproic acid concentration.
Serum concentrations of valproic acid (VPA) were reduced to 0% to 40% of the original levels by concomitant use with panipenem-betamipron (PAM-BP) in three patients. The serum VPA level began to decrease 2 days after the administration of PAPM-BP, and it began to increase within 24 hours of the last dose. The rapid change in the serum VPA level suggests the existence of unique and as yet unknown mechanisms of interaction between VPA and PAPM-BP. Epileptic seizures developed in two of the three patients during PAPM-BP use, which signaled the dangers of PAPM-BP administration to patients concomitantly administered VPA. PAPM-BP should not be used in patients administered VPA.
Yamagata
T
T
Department of Pediatrics, Jichi Medical School, Minamikawachi-machi, Tochigi, Japan.
Momoi
M Y
MY
Murai
K
K
Ikematsu
K
K
Suwa
K
K
Sakamoto
K
K
Fujimura
A
A
D000328:Adult; D000927:Anticonvulsants / Q000097:blood* / Q000627:therapeutic use; D002675:Child, Preschool; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000494:pharmacology*; D004827:Epilepsy / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D013845:Thienamycins / Q000009:adverse effects / Q000494:pharmacology; D014635:Valproic Acid / Q000097:blood* / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology
D000927:Anticonvulsants; D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron; D014635:Valproic Acid